DDC PHASE I/II STUDY IN CHILDREN WITH SYMPTOMATIC HIV INFECTION
DDC PHASE I/II STUDY IN CHILDREN WITH SYMPTOMATIC HIV INFECTION found dideoxycytidine (ddC) increased CD4 cell counts and decreased p24 antigen in eight of 15 and nine of 15 patients, respectively. The study, conducted by Philip Pizzo, National Cancer Institute, et al., involved an initial eight-week administration of ddC alone, followed by a regimen alternating ddC (one week) and AZT (three weeks). During the alternating cycle of ddC and AZT (Burroughs Wellcome's Retrovir), seven of 13 patients showed increases in CD4 count and six of eight had further drops or sustained lower levels of p24 antigen, the investigators noted. The research results were presented in a poster session June 6 at the International AIDS Conference in Montreal. Pizzo, et al., also reported that two children who presented with encephalopathy showed clinical improvement while receiving ddC alone. "However, ddC as a single agent did not improve the psychometric test results of the patients enrolled in the study," the investigators stated. As a single agent, ddC was tolerable during the eight-week administration, as was the alternating regimen of ddC and AZT. However, one patient, who had been intolerant to AZT, had dose-limiting neutropenia during the alternating regimen. Pizzo, et al., concluded that "although it is unlikely that ddC will be used as a single agent, its incorporation into combination regimens may be useful and deserves further study in children with AIDS."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth